Medpace Holdings Inc (NASDAQ:MEDP) reported an insider transaction in which President Jesse J. Geiger sold 31,707 shares of the company's common stock on March 17, 2026. The shares were sold at prices ranging from $451.36 to $460.288, bringing the gross proceeds of the sale to approximately $14.44 million.
The filing with the Securities and Exchange Commission also shows that Geiger exercised stock options to acquire 31,707 shares on the same date, with the exercise price set at $138.87 per share. The exercise represented a cash outlay of about $4.4 million. Those options had fully vested as of February 15, 2026, according to the Form 4.
At the time of the report, Medpace's shares were trading at $460.92, representing a 40.75% gain over the previous 12 months. Analysis from InvestingPro indicates that Medpace appears slightly overvalued at current pricing. The InvestingPro service is noted in the filing as offering 12 additional tips and Pro Research Reports for more detailed examination of MEDP's valuation and growth profile.
Analyst coverage of Medpace has shifted recently, with multiple firms altering ratings and initiating coverage:
- Barclays moved its rating to Equalweight from Underweight, commenting that valuation concerns have eased and that Medpace has narrowed its valuation gap relative to peers.
- RBC Capital initiated coverage with an Outperform rating, highlighting Medpace's operational efficiency as a contract research organization and its exposure to biopharma markets.
- TD Cowen upgraded the stock to Hold from Sell, but simultaneously lowered its price target, suggesting the current share price reflects fair value.
- Jefferies upgraded the company to Buy, citing improved biotech funding conditions in the second half of 2025 as a supporting factor.
- Baird raised its rating to Outperform and identified potential operational benefits from AI, setting a price target of $564.00.
These analyst moves illustrate a reappraisal of Medpace's outlook among research firms, with upgrades and new coverage reflecting a range of views about valuation, market positioning, and the drivers of future performance.
While the insider sale and option exercise are clearly documented in the SEC filing, the array of analyst actions and the InvestingPro valuation note provide additional context on how market participants are evaluating Medpace at current price levels.